Key concepts of clinical trials: A narrative review

Postgraduate Medicine

Volumn 123, Issue 5, 2011, Pages 194-204

  Umscheid, Craig A ^a,b   Margolis, David J ^b   Grossman, Craig E ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Drug development; Phase I trial; Phase II trial; Phase III trial; Phase IV trial; Randomized controlled trial

Indexed keywords

CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG RESEARCH; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH ETHICS; REVIEW;

CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CLINICAL TRIALS, PHASE IV AS TOPIC; DRUG EVALUATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES;

EID: 80052717039     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2011.09.2475     Document Type: Review

References (51)

1. American Recovery and Reinvestment Act of 2009. H.R. 1st ed; 2009.
2. Trials of War Criminals Before the Nuremberg Military Tribunals Under Control Council Law. No. 10, Vol. 2. Washington, DC: US Government Printing Office; 1949:181-182.
3. World Medical Organization. Declaration of Helsinki. December 7, 1996. BMJ. 1996:1448-1449.
4. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317(3):141-145.
5. Department of Health and Welfare. The Belmont report: ethical principles and guidelines for the protection of human subjects of research. Washington, DC: OPRR Reports; 1979.
6. Brandt AM. Racism and research: the case of the Tuskegee Syphilis Study. Hastings Cent Rep. 1978;8(6):21-29.
7. Code of Federal Regulations-The Common Rule: Protection of Human Subjects. In: Services DoHaH, ed. Vol 45. 2009.
8. Lansimies-Antikainen H, Laitinen T, Rauramaa R, Pietilä AM. Evaluation of informed consent in health research: a questionnaire survey. Scand J Caring Sci. 2010;24(1):56-64.
9. Ridpath JR, Wiese CJ, Greene SM. Looking at research consent forms through a participant-centered lens: the PRISM readability toolkit. Am J Health Promot. 2009;23(6):371-375.
10. Gravetter FJ, Forzano LAB. Research Methods for the Behavioral Sciences. 3rd ed. Belmont, CA: Wadsworth Cengage Learning; 2009.
11. Mapstone J, Elbourne D, Roberts I. Strategies to improve recruitment to research studies. Cochrane Database Syst Rev. 2007;(2):MR000013.
12. Treweek S, Mitchell E, Pitkethly M, et al. Strategies to improve recruitment to randomised controlled trials. Cochrane Database Syst Rev. 2010;(1):MR000013.
13. Dickert N, Grady C. What's the price of a research subject? Approaches to payment for research participation. N Engl J Med. 1999;341(3):198-203.
14. Prentice RL. Surrogate endpoints in clinical trials: defi nition and operational criteria. Stat Med. 1989;8(4):431-440.
15. Chobanian AV, Bakris GL, Black HR, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252.
16. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125(7):605-613.
17. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA. 1999;282(8):790-795.
18. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, fl ecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324(12):781-788.
19. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N Engl J Med. 1991;324(8): 509-516.
20. Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A. Biomarkers and surrogate end points-the challenge of statistical validation. Nat Rev Clin Oncol. 2010;7(6):309-317.
21. International Conference on Harmonisation. Good clinical practice guidelines for essential documents for the conduct of a clinical trial. Geneva, Switzerland: ICH Secretariat c/o IFPMA. 1994.
22. Roberts TG Jr, Goulart BH, Squitieri L, et al. Trends in the risks and benefi ts to patients with cancer participating in phase 1 clinical trials. JAMA. 2004;292(17):2130-2140.
23. Joffe S, Cook EF, Cleary PD, Clark JW, Weeks JC. Quality of informed consent in cancer clinical trials: a cross-sectional survey. Lancet. 2001;358(9295):1772-1777.
24. Eypasch E, Lefering R, Kum CK, Troidl H. Probability of adverse events that have not yet occurred: a statistical reminder. BMJ. 1995; 311(7005):619-620.
25. Cahana A, Romagnioli S. Not all placebos are the same: a debate on the ethics of placebo use in clinical trials versus clinical practice. J Anesth. 2007;21(1):102-105.
26. Foddy B. A duty to deceive: placebos in clinical practice. Am J Bioeth. 2009;9(12):4-12.
27. Wilcox CM. Exploring the use of the sham design for interventional trials: implications for endoscopic research. Gastrointest Endosc. 2008;67(1):123-127.
28. Levine RJ. The need to revise the Declaration of Helsinki. N Engl J Med. 1999;341(7):531-534.
29. Vastag B. Helsinki discord? A controversial declaration. JAMA. 2000;284(23):2983-2985.
30. Walker E, Nowacki AS. Understanding equivalence and noninferiority testing. J Gen Intern Med. 2011;26(2):192-196.
31. Fleming TR. Current issues in non-inferiority trials. Stat Med. 2008;27(3):317-332.
32. Doll R. Sir Austin Bradford Hill and the progress of medical science. BMJ. 1992;305(6868):1521-1526.
33. Hill AB. Medical ethics and controlled trials. Br Med J. 1963;1(5337): 1043-1049.
34. Scott NW, McPherson GC, Ramsay CR, Campbell MK. The method of minimization for allocation to clinical trials: a review. Control Clin Trials. 2002;23(6):662-674.
35. Tsiatis A. Methodological issues in AIDS clinical trials. Intent-to-treat analysis. J Acquir Immune Defi c Syndr. 1990;3(suppl 2):S120-S123.
36. Moher D, Schulz KF, Altman D; CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001;285(15):1987-1991.
37. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.
38. Fontanarosa PB, Rennie D, DeAngelis CD. Postmarketing surveillance- lack of vigilance, lack of trust. JAMA. 2004;292(21):2647-2650.
39. Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther. 1995;58(1):108-117.
40. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287(17):2215-2220.
41. Strom BL. Potential for confl ict of interest in the evaluation of suspected adverse drug reactions: a counterpoint. JAMA. 2004;292(21): 2643-2646.
42. AERS patient outcomes by year. In: Administration USFaD, ed. 2010. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070461.htm. Updated March 31, 2011. Accessed June 29, 2011.
43. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905-917.
44. Maro JC, Platt R, Holmes JH, et al. Design of a national distributed health data network. Ann Intern Med. 2009;151(5):341-344.
45. Berlin JA, Colditz GA. The role of meta-analysis in the regulatory process for foods, drugs, and devices. JAMA. 1999;281(9):830-834.
46. Hennekens CH, Demets D. The need for large-scale randomized evidence without undue emphasis on small trials, meta-analyses, or subgroup analyses. JAMA. 2009;302(21):2361-2362.
47. Mello MM, Studdert DM, Brennan TA. The rise of litigation in human subjects research. Ann Intern Med. 2003;139(1):40-45.
48. Steinbrook R. Protecting research subjects-the crisis at Johns Hopkins. N Engl J Med. 2002;346(9):716-720.
49. Ellenberg S, Fleming TR, DeMets DL. Data Monitoring Committees in Clinical Trials: A Practical Perspective: West Sussex, England: John Wiley & Sons; 2002.
50. Guidance for Industry. E6. Good clinical practice-consolidated guidance. Bethesda, MD: US Department of Health and Human Services; 1996.
51. Issa AM, Phillips KA, Van Bebber S, et al. Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. Curr Drug Saf. 2007;2(3):177-185.